JP2003517041A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517041A5
JP2003517041A5 JP2001545542A JP2001545542A JP2003517041A5 JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5 JP 2001545542 A JP2001545542 A JP 2001545542A JP 2001545542 A JP2001545542 A JP 2001545542A JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
seq
phosphodiester nucleotide
synthetic phosphodiester
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001545542A
Other languages
English (en)
Other versions
JP4772245B2 (ja
JP2003517041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2000/001467 external-priority patent/WO2001044465A2/en
Publication of JP2003517041A publication Critical patent/JP2003517041A/ja
Publication of JP2003517041A5 publication Critical patent/JP2003517041A5/ja
Application granted granted Critical
Publication of JP4772245B2 publication Critical patent/JP4772245B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 ３’−ＯＨ，５'−ＯＨ合成ホスホジエステルヌクレオチド配列、化学療法剤、及び薬学的に許容可能なキャリアを含む組成物であって、前記合成ホスホジエステルヌクレオチド配列は配列番号８−１０、２５、２６、４１−４３、４５及び４６からなる群から選択される、組成物。
【請求項２】 前記化学療法剤は、代謝拮抗物質、アルキル化剤又はホルモン拮抗物質である、請求項１に記載の組成物。
【請求項３】 前記合成ホスホジエステルヌクレオチド配列が配列番号８である、請求項１又は２に記載の組成物。
【請求項４】 前記合成ホスホジエステルヌクレオチド配列が配列番号９である、請求項１又は２に記載の組成物。
【請求項５】 前記合成ホスホジエステルヌクレオチド配列が配列番号１０である、請求項１又は２に記載の組成物。
【請求項６】 前記合成ホスホジエステルヌクレオチド配列が配列番号２５である、請求項１又は２に記載の組成物。
【請求項７】 前記合成ホスホジエステルヌクレオチド配列が配列番号２６である、請求項１又は２に記載の組成物。
【請求項８】 前記合成ホスホジエステルヌクレオチド配列が配列番号４１である、請求項１又は２に記載の組成物。
【請求項９】 前記合成ホスホジエステルヌクレオチド配列が配列番号４２である、請求項１又は２に記載の組成物。
【請求項１０】 前記合成ホスホジエステルヌクレオチド配列が配列番号４３である、請求項１又は２に記載の組成物。
【請求項１１】 前記合成ホスホジエステルヌクレオチド配列が配列番号４５である、請求項１又は２に記載の組成物。
【請求項１２】 前記合成ホスホジエステルヌクレオチド配列が配列番号４６である、請求項１又は２に記載の組成物。
JP2001545542A 1999-12-13 2000-12-12 治療上有用な合成オリゴヌクレオチド Expired - Fee Related JP4772245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US60/170,325 1999-12-13
US22892500P 2000-08-29 2000-08-29
US60/228,925 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (3)

Publication Number Publication Date
JP2003517041A JP2003517041A (ja) 2003-05-20
JP2003517041A5 true JP2003517041A5 (ja) 2008-02-07
JP4772245B2 JP4772245B2 (ja) 2011-09-14

Family

ID=26865979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001545542A Expired - Fee Related JP4772245B2 (ja) 1999-12-13 2000-12-12 治療上有用な合成オリゴヌクレオチド

Country Status (18)

Country Link
US (2) US7157436B2 (ja)
EP (2) EP1238070B1 (ja)
JP (1) JP4772245B2 (ja)
KR (1) KR100829646B1 (ja)
CN (2) CN100445380C (ja)
AT (2) ATE455851T1 (ja)
AU (1) AU785212B2 (ja)
CA (1) CA2393808A1 (ja)
CZ (1) CZ20022372A3 (ja)
DE (2) DE60036019T2 (ja)
DK (2) DK1238070T3 (ja)
ES (2) ES2288883T3 (ja)
HU (1) HUP0300627A3 (ja)
IL (2) IL150196A0 (ja)
MX (1) MXPA02005842A (ja)
NO (1) NO330508B1 (ja)
PT (1) PT1238070E (ja)
WO (1) WO2001044465A2 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CN100445380C (zh) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
EP1417307B1 (en) * 2001-08-17 2009-04-15 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use to induce apoptosis
EP1432450B1 (en) * 2001-10-03 2005-12-28 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
AU2003219383B2 (en) * 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7569554B2 (en) * 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
CA2598992A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1863538A4 (en) * 2005-03-09 2009-01-14 Baylor College Medicine DIRECT INVERSION OF CD4 + T CELL LYMPHOCYTE INHIBITOR FUNCTION VIA TOLL-TYPE 8 RECEIVER SIGNALING
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ES2658626T3 (es) * 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
TW201102073A (en) * 2009-07-15 2011-01-16 Enzon Pharmaceuticals Inc RNA antagonists targeting GLI2 for the treatment of leukemia
WO2013129603A1 (ja) * 2012-02-28 2013-09-06 国立大学法人東京農工大学 Tdp-43細胞内存在量関連疾患の認定方法
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
CA3242118A1 (en) * 2021-12-22 2023-06-29 Alfica Sehgal Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (ja) * 1971-11-19 1975-02-07 Anvar
CH602920A5 (ja) * 1973-02-23 1978-08-15 Wellcome Found
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
AU1456092A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
CA2268476A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
ATE179333T1 (de) * 1993-01-29 1999-05-15 Vetrepharm Inc Immunotherapeutische zubereitung
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
US6211431B1 (en) * 1994-08-30 2001-04-03 Commonwealth Scientific And Industrial Research Organization Plant transcription regulators from circovirus
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (ja) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
EA000841B1 (ru) * 1995-11-21 2000-04-24 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Антисмысловые олигонуклеотиды к ил-8 и рецептору ил-8 и способ лечения злокачественных опухолей
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
ATE383172T1 (de) * 1996-05-20 2008-01-15 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
DK1221955T3 (da) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
CN100445380C (zh) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
AU784356B2 (en) * 1999-12-28 2006-03-16 Bioniche Urology Ip Inc. Hyaluronic acid in the treatment of cancer
EP1432450B1 (en) * 2001-10-03 2005-12-28 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
AU2003219383B2 (en) * 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses

Similar Documents

Publication Publication Date Title
JP2003517041A5 (ja)
JP2002519061A5 (ja)
NZ522326A (en) Adenosine A2A receptor antagonists
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
JP2002060340A5 (ja)
JP2002535332A5 (ja)
JP2002532222A5 (ja)
RS50031B (sr) Triciklični inhibitori poli(adp-riboza)polimeraza
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
HUP0300527A3 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
MXPA03000661A (es) Catalizador metalico shell y un precursor del mismo, proceso para su preparacion y uso del catalizador.
JP2002510633A5 (ja)
EP1074549A3 (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
AU2002305236A8 (en) Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
ZA200106102B (en) Use of growth hormone secretagogues for improvement of functional health status.
ZA200105293B (en) Use of growth hormone secretagogues for treatment of physical performance decline.
GB2369617B (en) Novel 4,5-dihydroisoxazolylalkyl-piperazine or-piperidine derivatives having selective biological activity at dopamine D3orD4 receptor,and preparation thereof
JP2002506864A5 (ja)
JP2002540769A5 (ja)
CA2353205A1 (en) Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
MXPA03004498A (es) Uso de pirazolo (4,3-d)pirimidinas.
JP2003516751A5 (ja)
AU2001290989A1 (en) Treatment of inflammatory bowel disease by the administration of delta5-androstene-3beta-ol-7,17 dione and metabolizable precursors thereof
MXPA03004907A (es) Uso de pirazolo (4,3-d) pirimidinas.